In May 2016, the 10th Beijing Invention and Innovation Competition was held in Guotu Art Center. The competition announced and awarded all the awards of the 10th competition. The participating project of Beijing Dongfang Baitai Biotechnology Co., Ltd. is the long-acting Exendin-4 immune fusion protein. Dongfang Baitai JY09 project won the gold medal of Beijing Invention and Innovation Competition.

It is reported that the Beijing Invention and Innovation Competition was jointly organized by the Beijing Invention Association and the Beijing Workers' Technical Association under the guidance of the China Invention Association and the support of the Beijing Municipal Science and Technology Commission and the Beijing Federation of Trade Unions. Since the official launch of the competition, it has received great support from all walks of life. The project involves electronic information, energy and environment, biomedicine, new materials, advanced manufacturing, modern agriculture, etc. The competition has passed many links such as preliminary, semi-final, final, twice publicity and various evaluation forms. In recent years, many invention projects have been industrialized. More and more inventors have become leaders of technology enterprises.

The highly concerned JY09 project is a new class I biological drug for type II diabetes, which was independently developed by Beijing Dongfang Baitai Biotechnology Co., Ltd. after seven years of independent research and development by a research and development team composed of several high-level technical talents such as overseas returnees. At present, clinical approval documents have been obtained. JY09 project is a "triple" project supported by the national key new drug innovation. It is a special project supported and promoted by Beijing Municipal Science and Technology Commission. It is also a strategic emerging industry proposed in the Twelfth Five Year Plan for National Economic and Social Development of the People's Republic of China. The key technologies involved in the project technology, such as large-scale cell culture technology, serum free culture technology and long-term technology, belong to the high-tech fields supported by the state.

The JY09 project maintained its original biological activity while prolonging the half-life of Exendin-4 in vivo. Its efficacy is not lower than that of the currently marketed Exendin-4 short-term product. This drug breaks through the way of frequent injection of conventional drugs for diabetes three times a day, and is extended to once every 7-10 days, which greatly alleviates the pain and inconvenience of patients. It can significantly improve the blood sugar level of patients with type II diabetes, reduce the risk of hypoglycemia, and improve the safety of medication for patients. The cost of fermentation and purification is reduced through innovative molecular structure. Through innovative technology, we have obtained products with lower cost, which will benefit patients with type II diabetes in relieving their pain and reducing their economic burden. JY09 is bound to become a "blockbuster" in the field of biomedicine in China, with amazing market potential.

New exploration and innovation ---- guarantee for the enterprise to stay green

In the "11th Five-Year Plan" and "12th Five-Year Plan", the national action of innovation and development, driven by several policies to accelerate the development of the biological industry, established the strategic position of the biopharmaceutical industry and put forward more specific development strategies for the biopharmaceutical industry. In the long run, China's biopharmaceutical industry ushers in development opportunities. Dongfang Baitai firmly grasped this opportunity, followed the promotion of domestic policies and market demand, increased investment, introduced experienced overseas medical talents, and made substantial progress in independent research and development.

In addition to team innovation, Dongfang Baitai never forgot to guide every employee of the company. We strive to cultivate learning, knowledge, technology, expert and innovative workers. The Company has carried out in-depth technical innovation activities for employees to promote the technological progress of the enterprise and enhance the independent innovation ability and core competitiveness of the enterprise. Recently, it was jointly selected as the "Employee Innovation Studio" by the Federation of Trade Unions and the Science and Technology Bureau of Beijing Economic and Technological Development Zone.

The honor of "Employee Innovation Studio" will continue to mobilize the enthusiasm and initiative of the company's team to participate in innovative research and development, improve the innovation awareness and innovation level of employees, and meet the needs of employees for innovation and their desire to realize their own value. At the same time, it reflects the enterprise's respect for the needs of employees and recognition of the value of employees, and also realizes the maximum display of personal talents under the reasonable division of labor.

The acquisition of many honors shows that Dongfang Baitai has strong scientific research strength and resources in the field of biomedical innovation! The innovation research and development platform is in line with international standards, and the innovation research and development system is constantly improved. The award will lay a strong foundation for future research and bring confidence to the company and the team. We will continue to rely on scientific and technological innovation to improve the innovation and development capacity of enterprises, accelerate the promotion of the cultivation of highly skilled talents and the promotion and transformation of scientific and technological achievements - technological advantages will be transformed into market competitive advantages in a timely manner, break the monopoly of world pharmaceutical giants on advanced antibody drugs as soon as possible, contribute drugs with the meaning of "Chinese brand", and better benefit the people!